Nicholas P. Clayton,¹ Richard C. Khan-Malek,² Charles A. Dangler,³ Donghui Zhang,² Alexis Ascah,⁴ Malcolm Gains,⁴ Brent Gardner,⁵ Colleen Mockbee,⁵ Joan M. Keutzer,¹ John McManus,⁵ Simon Authier<sup>6,*

1</sup>Global Rare Diseases, Sanofi Genzyme, Cambridge, Massachusetts
²Global Biostatistics and Programming, Sanofi, Bridgewater, New Jersey
³Preclinical Safety, Sanofi, Framingham, Massachusetts
⁴Liminal Biosciences, Laval, Canada
⁵Partner Therapeutics, Inc, Lexington, Massachusetts
⁶Charles River Laboratories, Laval, Canada

^* Address for correspondence: Charles River Laboratories, 445, Boul Armand-Frappier, Laval, Quebec, H7V 4B3, Canada; email: simon.authier@crl.com.